TLR4 and Sepsis: used PLGA nanoparticles to deliver monophosphoryl lipid A (MPLA), a TLR4 agonist, to enhance the immune response against E. coli‐induced sepsis.[88] While both studies demonstrated significant potential in modulating TLR4‐mediated inflammation for enhancing sepsis therapy, their approaches differed: the first focused on antagonizing TLR4 to manage inflammation, while the second aimed to enhance the TLR4‐induced response to combat sepsis.